Technical Analysis for 0JXZ - Galapagos N.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 26.64 | 0.60% | 0.16 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.60% | |
| Shooting Star Candlestick | Bearish | 0.60% | |
| Reversal New Lows Setup | Bearish Swing Setup | 0.60% | |
| New 52 Week Low | Weakness | 0.60% | |
| Wide Bands | Range Expansion | 0.60% | |
| Oversold Stochastic | Weakness | 0.60% |
Get this analysis on your stocks daily!
Galapagos N.V. Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of"various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Classification
Keywords: Health Biotechnology Medicine Medical Specialties Biopharmaceutical Autoimmune Diseases Rheumatoid Arthritis Specialty Drugs Ulcerative Colitis Crohn's Disease Chronic Lymphocytic Leukemia Psoriatic Arthritis Rheumatology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 44.3 |
| 52 Week Low | 26.48 |
| Average Volume | 1,276 |
| 200-Day Moving Average | 35.42 |
| 50-Day Moving Average | 33.71 |
| 20-Day Moving Average | 30.14 |
| 10-Day Moving Average | 27.63 |
| Average True Range | 1.91 |
| RSI (14) | 21.26 |
| ADX | 30.63 |
| +DI | 7.80 |
| -DI | 19.92 |
| Chandelier Exit (Long, 3 ATRs) | 30.98 |
| Chandelier Exit (Short, 3 ATRs) | 32.20 |
| Upper Bollinger Bands | 35.50 |
| Lower Bollinger Band | 24.77 |
| Percent B (%b) | 0.17 |
| BandWidth | 35.62 |
| MACD Line | -2.16 |
| MACD Signal Line | -1.89 |
| MACD Histogram | -0.2614 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.34 | ||||
| Resistance 3 (R3) | 30.75 | 29.93 | 29.72 | ||
| Resistance 2 (R2) | 29.93 | 28.99 | 29.72 | 29.52 | |
| Resistance 1 (R1) | 28.28 | 28.40 | 27.87 | 27.87 | 29.31 |
| Pivot Point | 27.46 | 27.46 | 27.26 | 27.26 | 27.46 |
| Support 1 (S1) | 25.82 | 26.52 | 25.41 | 25.41 | 23.97 |
| Support 2 (S2) | 25.00 | 25.94 | 24.79 | 23.76 | |
| Support 3 (S3) | 23.35 | 25.00 | 23.56 | ||
| Support 4 (S4) | 22.94 |
